Histogen, Inc., a regenerative medicine company with a unique biological platform that replaces and regenerates tissues in the body, today announced its plans for clinical development of three key product candidates during the Company’s presentation at the HC...
Sept. 9, 2019 13:00 UTC Successful completion of Fractyl’s first sham-controlled, multicenter clinical trial of Revita DMR to support EU commercial launch and inform U.S. pivotal clinical trial Revita-2 data support Revita DMR as a non-pharmacological intervention...
MicuRx Pharmaceuticals, Inc., today announced positive top-line results for study MRX4-201, a US Phase 2 randomized, double-blind clinical trial comparing contezolid acefosamil (MRX-4) with linezolid for the treatment of acute bacterial skin and skin structure...
Alector, Inc. (ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001. AL001 is being evaluated for the...
CytoDyn Inc. (OTC.QB:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the FDA has allowed a...
Sept. 8, 2019 12:00 UTC 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary endpoint) Treatment emergent adverse events Grade 3 or higher were reported by 10 of 25 patients (safety as primary endpoint)...
Email
Text